{"date":"2025-07-02","count":8,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6936-2025-07-02-2116-197g4nq","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2025-07-02","time":"21:16:51","subject":"本公司法人董事之代表人異動暨三分之一以上董事發生變動","clause":"第6款","fact_date":"2025-07-02","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2025-07-02 21:16，「本公司法人董事之代表人異動暨三分之一以上董事發生變動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6564-2025-07-02-1733-1yj6do2","company_id":"6564","company":"安特羅","market":"興櫃","industry":"生技醫療","date":"2025-07-02","time":"17:33:20","subject":"代重要子公司 ENIMMUNE-RMT BIOTECH PTE. LTD.公告辦理減資變更登記完成","clause":"第35款","fact_date":"2025-07-02","cite_as":"公開資訊觀測站重大訊息：安特羅（6564），2025-07-02 17:33，「代重要子公司 ENIMMUNE-RMT BIOTECH PTE. LTD.公告辦理減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-07-02-1729-1pzjlpi","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-07-02","time":"17:29:18","subject":"公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-07-02 17:29，「公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6645-2025-07-02-1558-ois9r3","company_id":"6645","company":"金萬林-創","market":"上市","industry":"生技醫療","date":"2025-07-02","time":"15:58:05","subject":"公告本公司初次申請股票創新板上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2025-07-02","cite_as":"公開資訊觀測站重大訊息：金萬林-創（6645），2025-07-02 15:58，「公告本公司初次申請股票創新板上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2025-07-02-1531-9l1x2m","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-07-02","time":"15:31:51","subject":"代重要子公司Belite Bio, Inc公告LBS-008晚期乾性黃斑部病變之第三期臨床試驗收案完成","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-07-02 15:31，「代重要子公司Belite Bio, Inc公告LBS-008晚期乾性黃斑部病變之第三期臨床試驗收案完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2025-07-02-1035-1fqkmsr","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-07-02","time":"10:35:08","subject":"澄清媒體報導","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-07-02 10:35，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2025-07-02-1034-130sjnr","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2025-07-02","time":"10:34:52","subject":"澄清114/07/01媒體報導","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2025-07-02 10:34，「澄清114/07/01媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2025-07-02-0608-19w2x36","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2025-07-02","time":"06:08:53","subject":"本公司代子公司思捷優達股份有限公司公告YA-101用於多重系統退化症之第二期臨床試驗申請已獲日本PMDA核准","clause":"第44款","fact_date":"2025-07-02","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2025-07-02 06:08，「本公司代子公司思捷優達股份有限公司公告YA-101用於多重系統退化症之第二期臨床試驗申請已獲日本PMDA核准」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}